The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 353:951-952 September 1, 2005 Number 9
NextNext

Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Petersen, R. C.
-PubMed Citation
To the Editor: Petersen et al. (June 9 issue)1 report in their randomized, controlled trial of vitamin E, donepezil, and placebo in subjects with amnestic mild cognitive impairment that apolipoprotein E (APOE) {varepsilon}4 status had "a major modifying effect" and that "the benefit of donepezil was evident throughout the three-year follow-up" among carriers of APOE {varepsilon}4 alleles. This finding differs from those of prior studies in patients with Alzheimer's disease, which suggest that there is either no difference in the effect of cholinesterase inhibitors according to APOE {varepsilon}4 status2,3 or that there is a stronger treatment effect among . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.